Sunshine Biopharma Inc. (SBFMW) Gross margin 2019–2025
Sunshine Biopharma Inc. (SBFMW) gross margin by fiscal year — reported gross profit divided by reported revenue.
33.8%FY2025 · since FY2019: 47.7% → 33.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 33.8% | +3.2 pp |
| FY2024 | 30.6% | -4.0 pp |
| FY2023 | 34.6% | -4.4 pp |
| FY2022 | 39.0% | -9.4 pp |
| FY2021 | 48.4% | -15.4 pp |
| FY2020 | 63.8% | +16.1 pp |
| FY2019 | 47.7% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SBFMW financial trends
SBFMW RevenueSBFMW Net incomeSBFMW Net marginSBFMW Gross profitSBFMW Operating incomeSBFMW Operating marginSBFMW Operating cash flowSBFMW Free cash flowSBFMW Capital expendituresSBFMW Return on equitySBFMW Stock buybacksSBFMW Dividends paidSBFMW Total assetsSBFMW Total liabilitiesSBFMW Shareholders’ equitySBFMW overview →